GMP Manufacturing
Source: Nanoform
Nanoform’s GMP facility utilizes its award-winning Controlled Expansion of Supercritical Solutions (CESS®) technology for the manufacture of API nanoparticles to GMP standards.
Our capabilities include the ability to handle compounds with an OEL of 1 ug/m3 and above.
Furthermore, we are expanding our API manufacturing capacity in 2023 to include:
- Two new CESS® manufacturing suites in class-D cleanrooms that can handle highly potent compounds with an OEL of less than 30 ng/m3.
- Recipe control via automation, providing accurate and repeatable performance.
- Both CIP (Clean-in-Place) and WIP (Wash-in-Place) capabilities, enabling more efficient cleaning between campaigns, thereby reducing downtime and increasing API productivity.
Our GMP activities are regularly inspected by the national competent authority – the Finnish Medicines Agency (Fimea). Nanoform’s GMP Certificate is available on the EudraGMDP Database.
Contact us to discuss how our GMP manufacturing capabilities can support you.
Nanoform
This website uses cookies to ensure you get the best experience on our website. Learn more